Business
ANGLE: Completion of Fundraising and Acquisition
ANGLE: Completion of Fundraising and Acquisition.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2222V Angle PLC 01 November 2017 \n\n\n\n\n\nFor immediate release\n\n\n1 November 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nCompletion of Fundraising and Acquisition\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that further to the announcement of 30 October 2017 and General Admission earlier today, the Fundraising and Acquisition of certain assets of Axela Inc. is now complete. \n \nCapitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement entitled \"Acquisition and Fundraising\" released on 5 October 2017 unless the context requires otherwise.\n \n \nFor further information ANGLE:\n \n\n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nfinnCap Ltd (NOMAD and Joint Broker)\nCorporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne\nCorporate Broking - Alice Lane, Nikita Jain \n \n\n\n+44 (0) 207 220 0500\n\n\n\n\nWG Partners (Joint Broker)\nNigel Barnes, Nigel Birks, Andrew Craig, Chris Lee \n \n\n\n+44 (0) 203 705 9330\n \n\n\n\n\nFTI Consulting\nSimon Conway, Mo Noonan, Stephanie Cuthbert\nKimberly Ha (US) \n\n\n \n+44 (0) 203 727 1000\n+1 212 850 5612\n\n\n\n\n \n \n \nNotes for editors\n \nAbout ANGLE plc www.angleplc.com \n \nANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.\n \nANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the Unit...